-+ 0.00%
-+ 0.00%
-+ 0.00%

Berenberg Stays Positive on ALK-Abelló After 'Solid' Q3 Results; Buy Rating Kept

MT Newswires·11/19/2026 08:28:22
Listen to the news
08:28 AM EST, 11/19/2026 (MT Newswires) -- Berenberg remains positive about its investment case for ALK-Abelló (ALK-B.CO), with analysts noting the Danish allergy-focused pharmaceutical company's third-quarter results, thanks to growth in its tablet portfolio. "ALK delivered another set of solid results, with organic revenue growth of 15% driven by continued strong momentum in the tablet portfolio, which delivered 35% organic growth," according to a Thursday note. For 2026, ALK confirmed its outlook for revenue to increase between 16% and 17% in local currencies. As such, the research firm made "minor" estimate changes, mainly for 2026, and "slightly" lowered organic top-line projections for 2027 due to a stronger 2026 comparison base. Meanwhile, the stock's buy rating and price target of 300 kroner were left unchanged. "We remain positive about the investment case and anticipate ALK continuing to win in allergy immunotherapy, with a potentially very lucrative position being established within peanut allergy," analysts said.